“The Onsite FastTrack Review is not for the faint of heart. It is designed for customers who have their ducks in a row and are ready to go to market in Europe,” said Dr. Andre Routh, the BSI Senior Product Expert working with SynCardia. “We are working onsite with SynCardia to advance effectively toward European regulatory approval of the Companion Driver System.”
“SynCardia is taking advantage of a valuable opportunity by participating in the BSI FastTrack Program,” said Rodger Ford, CEO and president of SynCardia Systems, Inc., manufacturer of the CardioWest artificial heart. “Once we achieve regulatory approval in Europe and the U.S., we are projecting a 400% increase in the number of patients benefiting from the CardioWest artificial heart in the following 24 months.”
In Europe, CardioWest artificial heart patients can wait up to two years for a matching human heart. While demand is growing, the supply of donor hearts worldwide remains flat. In 2007, CardioWest implants accounted for 20 patient years of life on the artificial heart. In 2008, that number grew to 30, a 50% increase in patient years with only a 4% increase in the number of implants.
Discharge drivers allow stable CardioWest patients to enjoy a near-normal quality of life at home while they wait for a matching donor heart. Many of these patients can shop, travel, visit family and friends and live life like people with human hearts.
Originally designed as a permanent replacement heart, the CardioWest artificial heart is currently approved as a bridge to human heart transplant for patients dying from end stage biventricular failure.
The CardioWest artificial heart is the first and only FDA, Health Canada and CE Marking approved temporary Total Artificial Heart in the world. There have been more than 770 implants of the CardioWest artificial heart, accounting for more than 160 patient years of life on the device.
Contact:
SynCardia Systems, Inc. Director of Communications Don Isaacs, 520-955-0660 (cell)
Source: SynCardia Systems, Inc.
